Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker
<p>Abstract</p> <p>Background</p> <p>Tumor-associated antigens are appreciated as diagnostic markers, but they have also prompted tremendous efforts to develop tumor-specific immunotherapy. A previously cloned tumor-associated antigen, EBAG9, was initially defined by re...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2005-05-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/5/47 |
id |
doaj-aad4847d69634ea7926df5ea520f9d17 |
---|---|
record_format |
Article |
spelling |
doaj-aad4847d69634ea7926df5ea520f9d172020-11-25T00:18:34ZengBMCBMC Cancer1471-24072005-05-01514710.1186/1471-2407-5-47Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor markerDaniel PeterStein HaraldLehmann InsaErdmann BettinaAnagnostopoulos IoannisReimer Tatiana ADörken BerndRehm Armin<p>Abstract</p> <p>Background</p> <p>Tumor-associated antigens are appreciated as diagnostic markers, but they have also prompted tremendous efforts to develop tumor-specific immunotherapy. A previously cloned tumor-associated antigen, EBAG9, was initially defined by reactivity with the monoclonal antibody 22-1-1. Functionally, the EBAG9-encoded gene-product was believed to induce apoptosis in activated immune cells. However, using a cell-biological approach we identified EBAG9 as a Golgi-resident modulator of O-linked glycan expression, the latter product was then recognized by the 22-1-1 antibody. Secondly, EBAG9 expression was found physiologically in all murine tissues examined. This raised the question if EBAG9 is tumor-specific and mediates apoptosis itself or through O-linked glycans generated, among them the cognate 22-1-1 antigen Tn.</p> <p>Methods</p> <p>We have used immunohistochemistry to detect the expression of 22-1-1 and EBAG9 in various tissues. Correlation between expression of both antigens in cell lines was analysed by immunoblot and flow cytometry. Apoptosis was studied by using flow cytometry and Caspase-Glo™ 3/7 assay kit. Cellular distribution of EBAG9 was analysed by electron and confocal microscopy.</p> <p>Results</p> <p>Here, we compared expression of the 22-1-1 and EBAG9-defined antigens in normal and neoplastic tissues in situ. In contrast to 22-1-1 staining, EBAG9 is a ubiquitously expressed antigen in all normal and cancerous tissues. Functional studies on the role of 22-1-1 reactive material did not support any evidence for apoptosis induction. Employing electron and confocal microscopy, a refined subcellular localization of EBAG9 at the Golgi was obtained.</p> <p>Conclusion</p> <p>We suggest that the estrogen-inducible EBAG9 gene-product and the 22-1-1 defined antigen are structurally and functionally separate antigens.</p> http://www.biomedcentral.com/1471-2407/5/47 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Daniel Peter Stein Harald Lehmann Insa Erdmann Bettina Anagnostopoulos Ioannis Reimer Tatiana A Dörken Bernd Rehm Armin |
spellingShingle |
Daniel Peter Stein Harald Lehmann Insa Erdmann Bettina Anagnostopoulos Ioannis Reimer Tatiana A Dörken Bernd Rehm Armin Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker BMC Cancer |
author_facet |
Daniel Peter Stein Harald Lehmann Insa Erdmann Bettina Anagnostopoulos Ioannis Reimer Tatiana A Dörken Bernd Rehm Armin |
author_sort |
Daniel Peter |
title |
Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker |
title_short |
Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker |
title_full |
Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker |
title_fullStr |
Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker |
title_full_unstemmed |
Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker |
title_sort |
reevaluation of the 22-1-1 antibody and its putative antigen, ebag9/rcas1, as a tumor marker |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2005-05-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Tumor-associated antigens are appreciated as diagnostic markers, but they have also prompted tremendous efforts to develop tumor-specific immunotherapy. A previously cloned tumor-associated antigen, EBAG9, was initially defined by reactivity with the monoclonal antibody 22-1-1. Functionally, the EBAG9-encoded gene-product was believed to induce apoptosis in activated immune cells. However, using a cell-biological approach we identified EBAG9 as a Golgi-resident modulator of O-linked glycan expression, the latter product was then recognized by the 22-1-1 antibody. Secondly, EBAG9 expression was found physiologically in all murine tissues examined. This raised the question if EBAG9 is tumor-specific and mediates apoptosis itself or through O-linked glycans generated, among them the cognate 22-1-1 antigen Tn.</p> <p>Methods</p> <p>We have used immunohistochemistry to detect the expression of 22-1-1 and EBAG9 in various tissues. Correlation between expression of both antigens in cell lines was analysed by immunoblot and flow cytometry. Apoptosis was studied by using flow cytometry and Caspase-Glo™ 3/7 assay kit. Cellular distribution of EBAG9 was analysed by electron and confocal microscopy.</p> <p>Results</p> <p>Here, we compared expression of the 22-1-1 and EBAG9-defined antigens in normal and neoplastic tissues in situ. In contrast to 22-1-1 staining, EBAG9 is a ubiquitously expressed antigen in all normal and cancerous tissues. Functional studies on the role of 22-1-1 reactive material did not support any evidence for apoptosis induction. Employing electron and confocal microscopy, a refined subcellular localization of EBAG9 at the Golgi was obtained.</p> <p>Conclusion</p> <p>We suggest that the estrogen-inducible EBAG9 gene-product and the 22-1-1 defined antigen are structurally and functionally separate antigens.</p> |
url |
http://www.biomedcentral.com/1471-2407/5/47 |
work_keys_str_mv |
AT danielpeter reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker AT steinharald reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker AT lehmanninsa reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker AT erdmannbettina reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker AT anagnostopoulosioannis reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker AT reimertatianaa reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker AT dorkenbernd reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker AT rehmarmin reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker |
_version_ |
1725375783468269568 |